CJC-1295 with DAC (Drug Affinity Complex) is a long-acting GHRH analog that achieves its extended duration through a unique bioconjugation technology: the DAC component covalently bonds to circulating serum albumin after injection, using albumin as a long-lived carrier that extends the peptide's half-life from minutes (as with CJC-1295 No DAC) to 6–8 days per dose. This single pharmacokinetic modification transforms the dosing requirements from twice-daily injections to once or twice weekly, fundamentally changing the practical convenience of GHRH analog therapy.

The mechanism of GH stimulation is identical to CJC-1295 No DAC — both are synthetic analogs of the endogenous GHRH (1-44) sequence that bind and activate the pituitary GHRH receptor, stimulating somatotroph cells to release growth hormone. The difference is entirely pharmacokinetic: while CJC-1295 No DAC produces a sharp GH pulse over 2–3 hours (mimicking the pulsatile nature of physiological GHRH), DAC-CJC-1295 creates a continuous, sustained GHRH receptor stimulation that produces a prolonged GH elevation — commonly called "GH bleed" — persisting over multiple days from a single injection.

This distinction in release profile has practical implications. The natural pituitary GH secretion pattern is pulsatile — high-amplitude pulses released primarily during slow-wave sleep, with low trough levels between. Continuous GHRH receptor stimulation from DAC-CJC-1295 maintains elevated GH throughout the week rather than producing discrete pulses, which more closely mimics certain pathological GH excess states. The sustained elevation can produce trough-elevated IGF-1 levels and the associated benefits: continuous anabolic signaling, protein synthesis support, and lipolytic activity throughout the week.

The clinical trade-off between pulsatile (No DAC) and continuous (with DAC) GH release is a subject of ongoing discussion in the research community. Physiological GH pulsatility is important for maintaining receptor sensitivity — sustained elevation can lead to partial GHR desensitization over time. Many practitioners who have experience with both forms prefer CJC-1295 No DAC combined with GHRPs for the more physiological pulsatile pattern, reserving DAC-CJC for specific applications where sustained GH elevation and reduced injection frequency are prioritized.

For the appropriate user — one who values once or twice weekly injection convenience, benefits from sustained IGF-1 elevation, and is not concerned with strict physiological pulse replication — DAC-CJC-1295 provides the most convenient GHRH analog protocol available. Its long half-life means individual injection timing matters less, eliminating the need for precise daily scheduling. The 10mg vial provides 3–5 weeks of supply depending on whether weekly (3–4mg) or twice-weekly (2mg) dosing is employed.